182 results about "Nasal Drops" patented technology

A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate [UTP], dinucleotides, cytidine 5′-triphosphate [CTP], adenosine 5′-triphosphate [ATP], or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).

Addition of polyvinylpyrrolidone and a water-soluble anionic macromolecular compound to an aqueous suspension of a hardly soluble drug allows to provide an aqueous suspension in which aggregation of drug particles, formation of macro crystals from suspended particles and formation of secondary particles from deposited particles are prevented, and adhesion and adsorption to containers made of plastics, e.g., polypropylene or polyethylene, are avoided. As it has a good redispersibility, the aqueous suspension is useful as eye drops, nasal drops, ear drops, injections, oral preparations, liniments and lotions.

The preparation for intranasal administration comprising D-alanyl-3-(naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide (pralmorelin) and/or an acid addition salt thereof as an active ingredient and water permits a marked increase in the in vivo absorption of pralmorelin and hence provides adequate efficacy even if it is administered in a small dose at a time. The preparation also allows pralmorelin to be dissolved in an increased amount, so it can be formulated pharmaceutically with great ease. It also high stability over time.

The invention relates to liquid-state lipid micro-particles used for delivering a cerebric medicine through a nose olfactory pathway, a preparation method thereof, and a preparation thereof. The liquid-state lipid micro-particles at least comprise a medicine, a lipid material, a penetrating agent, hydroxyethyl starch, propylene glycol and water. The mass ratio of the medicine to the lipid material is 1:1 to 1:10. The volume ratio of propylene glycol to water is 2:1 to 1:10. The liquid-state lipid micro-particles are advantaged in large drug load, high deformation capacity, simple preparation method, and high entrapment rate. The micro-particles are beneficial for the medicine to be delivered into the brain through the nose olfactory pathway and to provide curative effects. The range of appropriate medicines of the liquid-state lipid micro-particles is large, and the liquid-state lipid micro-particles are especially suitable for hormone, polypeptide, gene or vaccine medicines. With the liquid-state lipid micro-particles, preparations such as aerosols, nasal drops, and gels can be produced, such that requirements of cerebric disease medication can be satisfied.

The invention discloses the drug of treating the nasal over-secretion and chronic obstructive emphysema, at the mean time, provides the drug compositions of treating the nasal over-secretion and chronic obstructive emphysema, which are aerosol, powder cloud agent, naristillae and spray. In the invention, the compositions, which are introduced quaternary ammonium group on the basis of penehyclidine hydrochloride, can't permeate membrane and enter into the circulatory system and central, so it can be used in treating the chronic obstructive emphysema. Besides, due to the low absorptivity in the mucous membrane position, the said new compositions are extended the resistance time at local, so it can be used in treating the chronic obstructive emphysema and coryza.

The invention discloses a method for separating and measuring moxifloxacin hydrochloride and an enantiomer thereof. According to the method, high performance liquid chromatography is adopted, a reversed phase column is used, a chiral reagent serves as a mobile phase, the enantiomer in the moxifloxacin hydrochloride is positioned according to a moxifloxacin hydrochloride racemate, the enantiomer of the moxifloxacin hydrochloride existing in various dosage forms including sustained release type, controlled release type or common tablets, capsules, granules, oral liquid, injection, eye drops, nasal drops, auristilla, suppository or injection can be checked, the quality standard of the conventional moxifloxacin hydrochloride is improved, and a basis is provided for setting an enantiomer measurement standard of the moxifloxacin hydrochloride in the future.

Disclosed is a drop agent for treating rhinitis and its preparing process, wherein the medicament comprises cocklebur fruit 18-30g, magnolia flower 9-15g, spearmint 9-15g, dahurian angelica root 9-15g, asarum herb 2-6g, gamene 12-20g, honeysuckle flower 12-20g, wild chrysanthemum flower 12-20g, licorice root 12-20g, herba schizonepetae 12-20g, Chinese ephedra 6-12g, yellow corktree bark 9-15g, anemarrhena rhizome 9-15g, schisandra fruit 12-20g, borneo camphor 8-12g, musk 0.4-0.8g and sesame oil 500g.

The invention discloses a recombinant porcine alpha interferon, prepared by the following methods: A1, synthesizing an artificially modified porcine alpha interferon; A2, constructing a recombinant eukaryotic expression vector pGAPZ alpha-IFN alpha; and A3, highly expressing IFN alpha by an eukaryotic cell yeast expression system. The invention is characterized by taking a supernatant to purifying the porcine alpha interferon which is cultured by a lot of engineering bacteria and expressed with a chromatography column, then collecting a target protein eluate, filtering through a 0.22 mum microfiltration membrane, then determining the activity by cytopathic inhibition, and calculating the potency unit according to 50% pathology; wherein the cell used for determination is Madin-Darby bovine kidney (MDBK), and vesicular stomatitis virus (VSV) is used for attacking the virus. According to the invention, the recombinant porcine alpha interferon obtained by purification is applied in controlling PCMV, and experiments prove that the recombinant porcine alpha interferon has obvious protection effect on PCMV infected cells. The route of administration of the porcine alpha interferon is injection or mucous membrane administration, and the dosage form comprises injection or nasal drops.

The present invention relates to the preparation and use of compositions for the treatment of skin disorders itchy and/or infected skin such as impetigo, acne (on face, forehead scalp and on the back of the body) and fungal infection of skin and nails. Whether the infection may be acute or chronic or sub-acute or acute on chronic.

As well as for the promotion of non carrier state of the human beings and animals from some pathogenic bacteria such as staphylococci. The compositions are based on extracts from the plants Cassia tora, Centratherum anthelminticum and/or Melia azadirachta. A variety of other herbal extracts may be included and the composition may take the form of a freeze dried or a spray dried powder or presence of this in a cream or ointment based on Ghee, or in a cream or ointment form developed with any other vehicle, or they may be in a powdered form without spray drying. That spray dried or freeze dried powder may be suspended in a suitable mouth wash or nasal drops. The herbs may be in a powdered form of suitable for preparing decoctions in hot water. Laboratory results are of Specimen Example 2. Specimen Example 1 I have found working on the patients clinically as broad spectrum covering pustules as well as fungal infections.

The invention belongs to medical technical field and discloses nasal mucosa medication agent of tetramethylpyrazine and the preparation method. The agent contains tetramethylpyrazine, pharmaceutical excipient and absorption enhancer. The weight percentage is 1:0.1 to 100:0.1 to 10. The tetramethylpyrazine includes tetramethylpyrazine prepared in various methods and salts of tetramethylpyrazine. Formula dosage of tetramethylpyrazine is put into absorption enhancer and additional pharmaceutical solutions of suitable concentration prepared in advance to produce nasal mucosa medication agent, such as nasal drops, spray, aerosol, microsphere agent, liposomes, etc. Via the special physiological structure of nasal cavity, the agent medicates via nasal mucosa and allows tetramethylpyrazine bypasses the blood-brain barrier to enhance the distribution of medicine in brain tissue. The drug can be used to treat migraine, cerebral ischemia, cerebral embolism and emergencies such as angina pectoris, coronary heart disease, myocardial infarction, etc, and the drug has the advantages of complete and rapid absorption, high treating effects, high stability, and few side effects.

The invention provides nasal drops used for anesthesia. The nasal drops are characterized in that dexmedetomidine hydrochloride injection and ketamine hydrochloride are adopted as the raw materials, an osmotic pressure regulator, a bacteriostatic agent, an antioxidant, a cosolvent and a pH value regulator with certain amount are added, the steps including concentrated preparation, diluted preparation, filling, sterilizing and externally packaging are carried out, and thus the nasal drops are obtained. For the nasal drops used for anesthesia, a special administration channel does not need to beestablished, so that no pain exists during the medication process of a patient, the compliance is good, the stability is good during the storage process of the product, deterioration due to crystallization does not exists, within the period of validity, the pH of the solution basically has no change, the microbial limit is qualified, the validity period of the product is as long as 24 months or alonger time, the increased amount of impurities during the preparation process is small, the increased amount of impurities during the whole preparation process is only 0.01%, the preparation processis simple and feasible, and the nasal drops are worthy of market promotion.

An oily nose drip is prepared from 12 Chinese-medicinal materials including xanthium fruit, asarum her, magnolia flower, astragalus root, etc through immersing in vegetable oil and decocting.

The invention discloses a traditional Chinese medicine compound preparation for treating rhinitis and nasosinusitis and a preparation process thereof. The preparation is prepared from the following raw materials in parts by weight or in parts by volume: 100-200 parts by weight of honeysuckle, 60-120 parts by weight of cocklebur fruit, 60-120 parts by weight of radix scrophulariae, 40-80 parts by weight of liquorice and 1-2 parts by volume of dementholized peppermint oil. The raw materials are taken and conventional accessories are added to the raw materials; and then the mixture is prepared according to the conventional process into nasal delivery preparations including but not limited to nose drops, nasal spray and nasal gel. The compound traditional Chinese medicine nasal delivery preparation provided in the invention is prepared by thoroughly extracting the main active ingredients of the raw materials and has obvious curative effect for treating rhinitis (comprising acute rhinitis, chronic rhinitis and allergic rhinitis) and nasosinusitis.

The invention discloses an application of composition containing borneol and drug loaded nanoparticles in treatment of cerebral diseases. The weight ratio of the borneol to the drug loaded nanoparticles is (1-5):(5-100), and an oral preparation, an injection or nasal drops are prepared from the borneol and the drug loaded nanoparticles. Borneol can promote the drug loaded nanoparticles to cross the blood brain barrier to enter cells, so that the uptake function of the drug loaded nanoparticles in intracerebral cells is enhanced, and the drug treatment effect is enhanced.

The invention discloses a pharmaceutical composition for treating nasal diseases, which is prepared from the following raw material medicaments: ephedrine hydrochloride, glycoside of baikal skullcap root, lily magnolia oil, boneol and honeysuckle flower. The pharmaceutical composition can be made into any clinically acceptable preparations through conventional methods in the prior art, preferably nasal drops, aerosols and sprays.

The present invention belongs to the field of pharmaceutical formulations in medicine, and discloses a nasal in situ gel delivery system, preparation and applications thereof, wherein particularly the system has great advantages in the fields of central nervous system drugs and protein peptide drugs. According to the present invention, the process for preparing the NGF nasal in situ gel preparation is a two-bottle method, wherein one bottle is an in situ gel solution, wherein poloxamer is preferably poloxamer P407 and the content is 16-16.8%, the polyethylene glycol is preferably PEG10000 and the content is 0.2-0.6%, the polysorbate is preferably Tween80 and the content is 1-3%, the preservative is preferably benzalkonium chloride and the content is 0.001-0.002%, the other bottle is NGF lyophilized powder preparation, the NGF content is 0.05-0.1%, the albumin content is 0.1-0.2%, the mannitol content is 5%, and before the use, the gel solution is added to the NGF lyophilized powder and uniform mixing is performed so as to obtain the system. According to the present invention, the disclosed drug delivery system can be used in any nasal administration dosage forms, preferably nasal drops and sprays; and with the nasal in situ gel delivery system, the difficult problem that the protein peptide drugs are used for the central nervous system is solved, and especially the application range for the nerve growth factor is expanded.

The invention relates to a butylphthalide nasal drop and a preparation method thereof. The butylphthalide nasal drop prepared by adopting the method has the advantages of good stability, quick effect, small size and simple preparation process, and is convenient to use, suitable for clinical first aid and suitable for industrialized production.

The invention discloses anti-anaphylactic rhinitis nasal drop. The anti-allergic nasal drop is characterized by comprising the following raw materials by weight: 8 to 13 grams of small centipeda herb, 1 to 3 grams of sharp-leaf galangal fruit, 3 to 7 grams of ephedra herb, 8 to 13 grams of beautiful sweetgum fruit, 8 to 13 grams of Siberian cocklour fruit, 8 to 13 grams of honeysuckle, 8 to 13 grams of mint, 8 to 13 grams of acorus gramineus, and 0.5 to 1.5 grams of borneol, and prepared by present method. The anti-allergic nasal drop has the advantages that: the raw materials are easily obtained, the cost is low, the treatment effect is remarkable and the like.